Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733596 | 1.00 | KDM4E (0.53) | KDM4ECD274KEAP1P2RX7SMN1; SMN2 | |
| SCHEMBL30811087 | 0.84 | KDM4E (0.56) | KDM4ESMN1; SMN2LMNAGRM4RAB9A | |
| SCHEMBL1680955 | 0.84 | KDM4E (0.56) | KDM4ESMN1; SMN2LMNAGRM4RAB9A | |
| SCHEMBL27797567 | 0.83 | KEAP1 (0.59) | KDM4ECD274KEAP1P2RX7SMN1; SMN2 | |
| SCHEMBL11138427 | 0.78 | KDM4E (0.66) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL6559354 | 0.78 | ALDH1A1 (0.40) | KDM4EKEAP1LMNARAB9ANPC1 | |
| SCHEMBL4799563 | 0.77 | SMN1; SMN2 (0.62) | KDM4EKEAP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL28709826 | 0.77 | KDM4E (0.41) | KDM4ESMN1; SMN2LMNAGRM4RAB9A | |
| SCHEMBL3291328 | 0.76 | KDM4E (0.49) | KDM4ECD274KEAP1P2RX7MEN1 | |
| SCHEMBL3294343 | 0.76 | CD274 (0.51) | KDM4ECD274KEAP1P2RX7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485708-B2 | Compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3986392-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114072135-A | Compounds for treating PD-L1 diseases | 凯莫森特里克斯股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020257549-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257549-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | KDM4E 1426/4885CD274 1/4885KEAP1 1956/4885 |
| US-11485708-B2 | Compounds for treatment of PD-L1 diseases | CD274, PDCD1, PDCD1LG2 | KDM4E 1426/4885CD274 1/4885KEAP1 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.